Article
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine in lactation.
Journal of pharmacokinetics and pharmacodynamics - 4 Apr 2025
Pan Xian, Rowland Yeo Karen
Abstract excerpt
About 15-20% of women experience postnatal depression and may seek advice about medication use whilst breastfeeding. Venlafaxine is a potent and selective neuronal serotonin-norepinephrine reuptake inhibitor indicated for treating major depressive disorders. The drug is mainly metabolised by cytochrome P450 2D6 (CYP2D6) to its active metabolite O-desmethylvenlafaxine (ODV), with small contributions from CYP2C9...
Read the complete abstract on PubMedTopics
- Models, Theoretical
- Genotype
- Breast Feeding
- Venlafaxine Hydrochloride
- Desvenlafaxine Succinate
